Stock Market & Financial Investment News

News Breaks November 26, 2012 18:04 EDT TSPT Transcept Pharmaceuticals announces broadened Intermezzo strategy Transcept Pharmaceuticals (TSPT) announced that Purdue Pharmaceutical Products, the Transcept U.S. commercialization partner for Intermezzo (zolpidem tartrate) sublingual tablet C-IV, is launching a national direct-to-consumer promotional campaign, including digital, print and television advertising to support Intermezzo commercialization. Intermezzo digital and print DTC campaigns began in November 2012 and television promotion is expected to begin in February 2013. Purdue has committed $19M to this consumer advertising campaign, and Transcept plans to provide an additional $10M. This $29M program will be primarily executed during the first six months of 2013. To reinforce the DTC promotional campaign, Purdue plans to utilize for the first time its established analgesic sales force, which consists of approximately 525 sales representatives, to promote Intermezzo to primary care prescribers and certain medical specialists. Purdue will continue to market Intermezzo to psychiatrists and other specialty prescribers with a specialty sales force of approximately 90 sales representatives who are exclusively devoted to Intermezzo. News For TSPT From The Last 14 Days Check below for free stories on TSPT the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 13, 2013 17:12 EDT TSPT Transcept Pharmaceuticals partner to stop using Intermezzo sales reps Subscribe for More Information May 10, 2013 07:25 EDT TSPT Transcept Pharmaceuticals downgraded to Hold from Buy at MLV Equity May 9, 2013 08:00 EDT TSPT Transcept downgraded to Market Perform from Outperform at JMP Securities JMP securities downgraded Transcept following weak script data for Intermezzo. 05:36 EDT TSPT Transcept downgraded to Market Perform from Outperform at Leerink Leerink downgraded Transcept Pharmaceuticals citing weak script data for Intermezzo and lowered its price target range for shares to $4-$5 from $7-$8. May 8, 2013 13:27 EDT TSPT Transcept Pharmaceuticals reports Q1 EPS (56c), consensus (36c) Transcept reported cash, cash equivalents and marketable securities of $81.1M at March 31. Sign up for a free trial to see the rest of the stories you've been missing.